In Depth 7 May 2025 Unlocking immunity: the power of TLR agonists Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial. May 7, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Apr 2025 Seven biotechs to watch in the hepatitis B space Here we take a look at seven biotechs with clinical drug candidates on a quest to win regulatory approval to treat HBV. April 22, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 3 Apr 2024 Hepatitis B: are we edging closer to a cure? Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease. April 3, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Vaccitech announces positive topline data for chronic hepatitis study Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […] March 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Vir Biotech presents new data for functional cure of chronic Hep B virus Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Ascentage Pharma gives positive news on chronic hepatitis B drug Ascentage Pharma has released results from a phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB). The results were presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting […] November 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Swedish researchers developing new treatment for chronic hepatitis B and D infections A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet in Sweden, have been published in the journal Gut. Chronic infections of the hepatitis B virus (HBV) and hepatitis […] August 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine The National Institute of Allergy and Infectious Disease (NIAID) has awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes hepatitis C. Hepatitis C is an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus (HCV) […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Eiger BioPharmaceuticals presents liver study data Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […] June 28, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Study reveals progress for those with hepatitis B A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Aug 2020 Is Hepatitis D Healthcare Being Overlooked? Despite the recent EU approval of the first hepatitis D treatment, low public awareness remains an obstacle to tackling this aggressive infection. Earlier this month, the peptide drug Hepcludex became the first drug greenlit for hepatitis D treatment in Europe. This was a conditional market authorization granted to the German company MYR Pharmaceuticals based on […] August 20, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email